Lv41
596 积分 2021-04-09 加入
Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
5天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
19天前
已完结
At the Crossroads of Local and Systemic Treatment of Operable Non–Small Cell Lung Cancer
19天前
已完结
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
1个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
1个月前
已完结
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
1个月前
已完结
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
1个月前
已完结
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC
1个月前
已完结
皖公网安备34019202002308
